Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Metformin GR: Phase III

In a 250-patient open-label, 24-week extension of a double-blind, placebo-controlled U.S.

Read the full 114 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE